Caliway Closes Oversubscribed Capital Raise and Secures Over $100M to Advance CBL-514 Pivotal Phase 3 Study in Subcutaneous Fat Reduction
TAIPEI, Dec. 16, 2023 /PRNewswire/ — Caliway Biopharmaceuticals (Caliway) announced that it has closed an oversubscribed capital raise, securing over…
